Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 24

Trial Status

Recruiting4

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT07731789Phase 2Recruiting
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
Classic Follicular LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+1 more
PrincipalinvestigatorStart date: 2026-10-09
NCT07097363Phase 2Recruiting
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
B-Cell Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
PrincipalinvestigatorStart date: 2025-12-07
NCT06948786Phase 2Recruiting
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Grade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma+2 more
PrincipalinvestigatorStart date: 2025-11-17
NCT06784726Phase 2Recruiting
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+9 more
PrincipalinvestigatorStart date: 2025-09-04

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Joseph M Tuscano

University of California, Davis

Related
5 trials

Shared therapeutic areas:

Recurrent Follicular LymphomaRefractory Follicular LymphomaGrade 1 Follicular Lymphoma+7 more
Similarity Score11%

Ryan Lynch

Fred Hutch/University of Washington Cancer Consortium

Related
5 trials

Shared therapeutic areas:

Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+6 more

Worked with same sponsors:

University of Washington
Similarity Score10%

Ajay Gopal

Fred Hutch/University of Washington Cancer Consortium

Related
8 trials

Shared therapeutic areas:

Grade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma+4 more

Worked with same sponsors:

University of Washington
Similarity Score8%

Jordan Gauthier

Fred Hutch/University of Washington Cancer Consortium

Related
5 trials

Shared therapeutic areas:

Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaB-cell Non-Hodgkin Lymphoma+3 more
Similarity Score7%

Yago L Nieto

M.D. Anderson Cancer Center

Related
5 trials

Shared therapeutic areas:

Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+2 more
Similarity Score6%

Alex F Herrera

City of Hope Medical Center

Related
9 trials

Shared therapeutic areas:

Recurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRefractory Diffuse Large B-Cell Lymphoma+1 more
Similarity Score4%

Tanya Siddiqi

City of Hope Medical Center

Related
5 trials

Shared therapeutic areas:

High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma
Similarity Score3%

Rachel B. Salit

Fred Hutch/University of Washington Cancer Consortium

Related
4 trials

Shared therapeutic areas:

Burkitt LymphomaRecurrent Follicular Lymphoma

Worked with same sponsors:

Incyte Corporation
Similarity Score2%

Elias Jabbour, MD

M.D. Anderson Cancer Center

Related
15 trials

Shared therapeutic areas:

High Grade B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Similarity Score2%

Mark J Roschewski, M.D.

National Cancer Institute (NCI)

Related
8 trials

Shared therapeutic areas:

Burkitt LymphomaPrimary Mediastinal Large B-Cell Lymphoma
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT07731789Phase 2PrincipalInvestigator

Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

Classic Follicular LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+1 more
Recruiting
NCT07097363Phase 2PrincipalInvestigator

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

B-Cell Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
Recruiting
NCT06948786Phase 2PrincipalInvestigator

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Grade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma+2 more
Recruiting
NCT06784726Phase 2PrincipalInvestigator

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+9 more
Recruiting

All 4 trials loaded